| Literature DB >> 30464419 |
Fei Bai1,2,3,4, Juan Ling1,2,3, Gloria Esoimeme5, Liang Yao1,2,3, Mingxia Wang1,6, Jiajun Huang1,7, Anchen Shi1,6, Zehui Cao1,7, Yaolong Chen1,2,3, Jinhui Tian1,2,3, Xiaoqin Wang1,2,3, Kehu Yang1,2,3.
Abstract
OBJECTIVE: We conducted a systematic review to evaluate questionnaires about patient's values and preferences to provide information on the most appropriate questionnaires to be used when developing clinical practice guidelines.Entities:
Keywords: Patient Satisfaction; guideline; patient’s values and preferences; questionnaires; systematic review
Year: 2018 PMID: 30464419 PMCID: PMC6220727 DOI: 10.2147/PPA.S177540
Source DB: PubMed Journal: Patient Prefer Adherence ISSN: 1177-889X Impact factor: 2.711
Items of the psychometric methods
| The item generation phase should include all important elements of patient’s preferences by reviewing the existing questionnaires, literature, and opinions from experts and patient focus groups. The authors should describe the generation of initial items, including literature review, | ⎕ Yes |
| ⎕ No | |
| ⎕ Uncertain | |
| ⎕ Not applicable | |
| The authors should state that they pretested the items of questionnaires. The process of pretest and pilot testing is for revision of the questionnaire into the final validated version by using the response from the protest group. Items with ambiguous meanings can be eliminated to maximize the reliability and validity of the questionnaire. | ⎕ Yes |
| ⎕ No | |
| ⎕ Uncertain | |
| ⎕ Not applicable | |
| ⎕ Yes | |
| ⎕ No | |
| ⎕ Uncertain | |
| ⎕ Not applicable | |
| The authors should state that they tested the reliability. | ⎕ Yes |
| ⎕ No | |
| ⎕ Uncertain | |
| ⎕ Not applicable | |
| ⎕ Yes | |
| ⎕ No | |
| ⎕ Uncertain | |
| ⎕ Not applicable |
Figure 1Trial selection flow chart.
Characteristics of included studies
| Author (year) | Disease domain | Study design | Study duration (months) | Setting | No of patients | Provided training to patients | Calculated sample size | Involved family members | Examined knowledge about diseases |
|---|---|---|---|---|---|---|---|---|---|
| Bo et al (2014) | Lung cancer | NR | 19 | Inpatient | 135 | NR | NR | No | Yes |
| Welsh and Tiffin (2014) | Psychosis | Brief self-report survey | 3 | NR | 75 | NR | NR | Yes | No |
| Vu et al (2015) | Colonoscopy | Single-center, prospective survey | NR | Outpatient | 500 | Yes | NR | No | Yes |
| Tong et al (2016) | Lung cancer | Pilot study | NR | NR | 225 | Yes | NR | No | Yes |
| Sekimoto et al (2004) | T2DM | NR | 3 | Outpatient | 133 | Yes | NR | Yes | Yes |
| Rid et al (2015) | Incapacity | Self-administered quantitative survey | 20 | Inpatient Outpatient | 1,116 | Yes | Yes | No | Yes |
| Noble et al (2015) | Thrombosis | Conjoint analysis surveys | NR | Inpatient | 100 | Yes | Yes | No | No |
| Mazur et al (1999) | Prostate cancer | Cross-sectional study | NR | Outpatient | 228 | Yes | NR | No | Yes |
| Matti et al (2010) | Optic neuritis | NR | 5 | Outpatient | 27 | Yes | NR | No | Yes |
| Maciver et al (2016) | Heart failure | Qualitative study | 12 | Outpatient | 25 | NR | Yes | No | Yes |
| Sanford et al (2014) | Myeloid leukemia | NR | 3 | Outpatient | 56 | Yes | NR | Yes | Yes |
| Koh et al (2010) | ACL reconstruction | NR | 22 | Outpatient | 129 | Yes | NR | No | Yes |
| Ha and Mcdonald (2017) | Preterm birth | Cross-sectional survey | 2 | Outpatient | 311 | No | Yes | Yes | Yes |
| Gareen et al (2015) | Colorectal cancer | NR | 12 | Outpatient | 2,310 | No | NR | No | Yes |
| Fiks et al (2013) | ADHD | NR | 6 | Outpatient | 148 | No | NR | Yes | Yes |
| Eckman et al (2015) | Thrombus | Cross-sectional study | NR | Outpatient | 123 | Yes | NR | No | Yes |
| Choudhry et al (2015) | Melanoma | NR | 12 | Outpatient | 301 | NR | NR | No | No |
| Calderwood et al (2011) | Colorectal cancer | Cross-sectional survey | 14 | Outpatient | 100 | Yes | Yes | No | Yes |
| Bolge et al (2016) | RA | Self-administered online survey | NR | Outpatient | 243 | No | NR | No | Yes |
| Hofman et al (2011) | T1DM | Open-label, randomized, crossover usability test | NR | Inpatient | 15 | Yes | NR | Yes | Yes |
Abbreviations: ACL, anterior cruciate ligament reconstruction; ADHD, attention deficit/hyperactivity disorder; NR, not reported; RA, rheumatoid arthritis; T1DM, type 1 diabetes mellitus; T2DM, type 2 diabetes mellitus.
Characteristics of included questionnaires
| Questionnaire from studies | Mode of administration | Format | Incentives | Ethics statement | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| No of items | No of pages | The setting of the question options for the questionnaires | No of sections | Response options (No of items) | Range of scores | Anonymous | Informed consent | |||
| Bo et al (2014) | NR | 9 | 1 | SCQ | 2 | – | – | NR | Yes | Yes |
| Welsh and Tiffin (2014) | Interview | 10 | 3 | CT | 4 | 4-point scale (10) | Very likely, likely, unlikely, very unlikely | NR | NR | Yes |
| Vu et al (2015) | Interview | 12 | 2 | SCQ+CT+OeQ | 2 | 4-point scale (3) | Very important to not important at all | NR | Yes | NR |
| Tong et al (2016) | Interview | 50 | 17 | SCQ+CT | 4 | 5-point scale (3) | Strongly prefer left, somewhat prefer left, indifferent, somewhat prefer right, strongly prefer right | Yes | Yes | Yes |
| Sekimoto et al (2004) | Interview | 7 | 2 | SCQ+CT | 2 | – | – | NR | Yes | Yes |
| Rid et al (2015) | Interview | 46 | 6 | SCQ+CT+OeQ | 4 | 4-point scale (23) | Extremely important, moderately important, just a little important, not important at all | NR | Yes | NR |
| Noble et al (2015) | Interview | 10 | 7 | SCQ+CT+OeQ | 2 | 5-point scale (10) | Do not agree at all to fully agree | NR | Yes | Yes |
| Mazur et al (1999) | Interview | 2 | 1 | SCQ+OeQ | 1 | – | – | NR | NR | Yes |
| Matti et al (2010) | Interview | 19 | 3 | MCQ+SCQ | 3 | – | – | NR | Yes | Yes |
| Maciver et al (2016) | Interview | 6 | 3 | SCQ+OeQ | 2 | – | – | NR | Yes | Yes |
| Sanford et al (2014) | Interview | 18 | 4 | SCQ+CT+OeQ | 5 | 5-point scale (11) | Nil, minor, tolerable, tolerable but I adjust my activities or take medications for it, intolerable | NR | Yes | Yes |
| Koh et al (2010) | NR | 7 | 1 | MCQ+SCQ | 1 | – | – | NR | Yes | Yes |
| Ha and Mcdonald (2017) | NR | 17 | 6 | SCQ+CT | 6 | 5-point scale (3) | Extremely important, slightly important, neutral, slightly not important, not at all important | NR | Yes | NR |
| Gareen et al (2015) | Interview | 3 | 9 | SCQ+OeQ | 6 | – | – | NR | NR | NR |
| Fiks et al (2013) | Interview | 9 | 1 | CT | 3 | 6-point scale (9) | Not at all, a little, somewhat, very much, completely | NR | Yes | Yes |
| Eckman et al (2015) | Interview | 2 | 1 | SCQ | 2 | – | – | NR | Yes | Yes |
| Choudhry et al (2015) | Interview | 11 | 4 | SCQ+CT+OeQ | 3 | – | – | NR | No | Yes |
| Calderwood et al (2011) | Interview | 20 | 12 | SCQ+CT | 3 | 5-point scale (13) | Strongly agree, agree, neither agree nor disagree, disagree, strongly disagree | Yes | Yes | Yes |
| Bolge et al (2016) | online survey | 11 | 3 | SCQ+CT | 2 | 5-point scale (2) 4-point scale (1) | Not at all open, not very open, somewhat open, very open, extremely open; strongly prefer self-injection to strongly prefer IV infusion | NR | Yes | Yes |
| Hofman et al (2011) | Interview | 13 | 2 | CT+OeQ | 2 | 6-point scale (13) | Very difficult–very easy; not at all likely–very likely | NR | Yes | Yes |
Abbreviations: CT, choice task; IV, intravenous; MCQ, multiple-choice question; NR, not reported; OeQ, open-ended question; SCQ, single-choice question.
The evaluation of components of questionnaires
| Item generation | Pilot testing and redesign | Validity testing | Reliability testing (Cronbach’s α) | Acceptability
| ||
|---|---|---|---|---|---|---|
| Time to complete | Response rates | |||||
|
| ||||||
| Bo et al (2014) | No | No | No | No | No | No |
| Welsh and Tiffin (2014) | No | No | No | No | No | Yes |
| Vu et al (2015) | No | No | No | No | No | No |
| Tong et al (2016) | Yes | Yes | No | No | Yes | Yes |
| Sekimoto et al (2004) | No | No | Yes | No | No | Yes |
| Rid et al (2015) | Yes | Yes | Yes | No | Yes | Yes |
| Noble et al (2015) | Yes | No | Yes | No | Yes | No |
| Mazur et al (1999) | No | No | No | No | No | No |
| Matti et al (2010) | Yes | No | No | No | Yes | Yes |
| Maciver et al (2016) | Yes | Yes | No | No | No | No |
| Sanford et al (2014) | No | No | No | No | Yes | Yes |
| Koh et al (2010) | Yes | No | Yes | No | No | No |
| Ha and Mcdonald (2017) | Yes | No | Yes | No | Yes | Yes |
| Gareen et al (2015) | No | No | Yes | No | Yes | Yes |
| Fiks et al (2013) | Yes | Yes | Yes | Yes | No | Yes |
| Eckman et al (2015) | Yes | No | No | No | No | No |
| Choudhry et al (2015) | Yes | No | No | No | No | Yes |
| Calderwood et al (2011) | No | No | No | No | Yes | No |
| Bolge et al (2016) | No | No | No | No | Yes | No |
| Hofman et al (2011) | No | No | No | No | No | No |
Summary of domains and items for reviewing the questionnaires addressing values and preferences
| Domain | Study ID, author (year) | Examples | Scale | Type of disease |
|---|---|---|---|---|
| The convenience of treatment | Bolge et al (2016) | Would you prefer to take your biologic medication by self-injection at home or have the medication given to you by a health care professional through intravenous infusion? | 5-point scale | RA |
| Hofman et al (2011) | How easy or difficult it was to detach/remove the needle cap? | 6-point scale | Adolescents with diabetes | |
| The frequency required for testing | Calderwood et al (2011) | Which of the following attributes most influences your choice? | SCQ | Colorectal cancer |
| The types of drug preparations and therapy | Welsh and Tiffin (2014) | How likely would you be to accept this kind of support? | 4-point scale | Psychosis |
| The benefit of the interventions | Ha and Mcdonald (2017) | Did the medication work very well? (extremely important, slightly important, neutral, slightly not important, not at all important) | 5-point scale | Premature or early birth |
| Ha and Mcdonald (2017) | When considering cerclage treatment, how important or unimportant is each of the following | 5-point scale | Premature or early birth | |
| Sekimoto et al (2004) | Regarding the treatment options, what kind of information do you require? | SCQ | T2DM | |
| Treatment time | Tong et al (2016) | If these procedures were identical in all other ways, which would you prefer? | SCQ | Lung cancer |
| Tong et al (2016) | What bothers you the most about focus radiation? | SCQ | Lung cancer | |
| The frequency of drug administration | Noble et al (2015) | Which frequency of administration do you prefer? | SCQ | Cancer-associated thrombosis |
| Sanford et al (2014) | How likely are you to take your medications every day? | 5-point scale | CML | |
| Hospital stay time | Tong et al (2016) | What bothers you the most about open surgery? | SCQ | Lung cancer |
| The risk of adverse effects | Bo et al (2014) | Reasons for treatment decision making (choose the three answers with the most consideration): | SCQ | Lung cancer |
| The risk of complications | Ha and Mcdonald (2017) | When considering cerclage treatment, how important or unimportant is each of the following: | 5-point scale | Premature or early birth |
| Calderwood et al (2011) | Which of the following attributes mostly influences your choice? | 5-point scale | Colorectal cancer | |
| Communicating the risk of the interventions | Mazur et al (1999) | Which do you prefer when your physician communicates to you the risk of the intervention? | SCQ | Lung cancer |
| Sekimoto et al (2004) | Regarding the treatment options, what kind of information do you require? | SCQ | T2DM | |
| The risk of disease transmission | Koh et al (2010) | If you choose the allograft, what are the reasons for it? | MCQ | ACL reconstruction |
| The risk of relapse | Sanford et al (2014) | In the following questions, if the risk of relapse is different, how likely are you to stop medications for your CML? If the risk of relapse were 20%, 40%, 60%?, I would absolutely stop, I would likely stop, I would be neutral, I would likely not stop, I would absolutely not stop | SCQ | CML |
| Sekimoto et al (2004) | Regarding the treatment options, what kind of information do you require? | SCQ | T2DM | |
| Matti et al (2010) | What is your view about having an action plan in the event of a relapse? | SCQ | Optic neuritis | |
| Better healing after treatment/recover time | Koh et al (2010) | If you choose the allograft, what are the reasons for it? | MCQ | ACL |
| The cost patients have to pay | Ha and Mcdonald (2017) | When considering cerclage treatment, how important or unimportant is each of the following | 5-point scale | Premature or early birth |
| Calderwood et al (2011) | Which of the following attributes mostly influences your choice? | SCQ | Colorectal cancer | |
| Koh et al (2010) | If you choose the allograft, what are the reasons for it? | MCQ | ACL reconstruction | |
| Physician’s experience | Tong et al (2016) | How important is your physician’s experience to you? | 4-point scale | Lung cancer |
| Physician’s recommendation | Bolge et al (2016) | When deciding on a treatment for rheumatoid arthritis, which of the following best applies? | 5-point scale | RA |
| Bolge et al (2016) | How open are you to having your RA medication administered at home by self-injection if your rheumatologist suggested it? | 5-point scale | RA | |
| Sekimoto et al (2004) | Regarding the treatment options, what kind of information do you require? | SCQ | T2DM | |
| Bolge et al (2016) | When deciding on a treatment for rheumatoid arthritis, which of the following best applies? | 5-point scale | RA | |
| Koh et al (2010) | If you choose the allograft, what are the reasons for it? | MCQ | ACL reconstruction | |
| Bo et al (2014) | Reasons for treatment decision-making: (choose the three answers with the most consideration) | SCQ | Lung cancer | |
| Initiation of the decision process | Maciver et al (2016) | Who do you think should start these discussions? | OeQ | ICD treatment |
Abbreviations: ACL, anterior cruciate ligament; CML, chronic myeloid leukemia; ICD, implantable cardioverter-defibrillators; MCQ, multiple-choice question; OeQ, subjective questions; RA, rheumatoid arthritis; SCQ, single-choice questions; T2DM, type 2 diabetes mellitus.